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Abstract
Background: China is one of ten countries with the highest prevalence rate of pneumococcal infections. However,
there is limited serotype surveillance data for Streptococcus pneumoniae, especially from the community or rural
regions, partly due to limited serotyping capacity because Quellung serotyping is only available in few centers in
China. The aim of this study was to develop a simple, practical and economic pneumococcal serotype prediction
strategy suitable for future serotype surveillance in China.
Methods: In this study, 193 S. pneumoniae isolates were collected from hospitalized children, 96.9 % of whom were
< 5 years old. The cpsB sequetyping, complemented by selective and modified USA CDC sequential multiplex-PCR,
was performed on all the isolates, and serotypes 6A-6D specific PCRs were done on all serogroup 6 isolates. Based
on systematic analysis of available GenBank cpsB sequences, we established a more comprehensive cpsB sequence
database than originally published for cpsB sequetyping. Antibiotic susceptibility of all isolates was determined
using the disk diffusion or E-test assays.
Results: We built up a comprehensive S. pneumoniae serotype cpsB sequetyping database for all the 95 described
serotypes first, and then developed a simple strategy for serotype prediction based on the improved cpsB
sequetyping and selective multiplex-PCR. Using the developed serotype prediction strategy, 191 of 193 isolates
were successfully “serotyped”, and only two isolates were “non-serotypeable”. Sixteen serotypes were identified
among the 191 “serotypeable” isolates. The serotype distribution of the isolates from high to low was: 19 F (34.7 %),
23 F (17.1 %), 19A (11.9 %), 14 (7.3 %), 15B/15C (6.7 %), 6B (6.7 %), 6A (6.2 %), 9 V/9A (1.6 %); serotypes 6C, 3, 15 F/
15A, 23A and 20 (each 1.1 %); serotypes 10B, 28 F/28A and 34 (each 0.5 %). The prevalence of parenteral penicillin
resistance was 1.0 % in the non-meningitis isolates and 88.6 % in meningitis isolates. The total rate of multidrug
resistance was 86.8 %.
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Conclusions: The integrated cpsB sequetyping supplemented with selective mPCR and serotypes 6A-6D specific
PCRs “cocktail” strategy is practical, simple and cost-effective for use in pneumococcal infection serotype
surveillance in China. For hospitalized children with non-meningitis penicillin-susceptible pneumococcal infections,
clinicians still can use narrow-spectrum and cheaper penicillin, using the parenteral route, rather than using
broader-spectrum and more expensive antimicrobials.
Keywords: Streptococcus pneumoniae, serotype prediction, cpsB sequetyping, Sequential multiplex PCR, Antibiotic
multidrug resistance
Background
Streptococcus pneumoniae is a leading cause of bacterial
pneumonia, meningitis, and sepsis in children world-
wide. Although China is among the ten countries with
the highest prevalence of pneumococcal cases [1], there
is limited epidemiological data on invasive pneumococ-
cal disease in mainland China. Vaccination, targeting the
pneumococcal polysaccharide capsule, is the best way to
prevent pneumococcal disease, especially in children.
The 7-valent pneumococcal conjugate vaccine (PCV7),
which is no longer available, became accessible for the
private sector in China in September 2008 [2], but was
never part of the universal immunization program in
this country. Even in Shenzhen (one of the biggest cities
in China which borders Hong Kong), the PCV7
immunization rate is still less than 1 % [3].
The capsular polysaccharide is the main virulence de-
terminant of S. pneumoniae, and structural differences
of this polysaccharide, can divide S. pneumoniae into
many serotypes. After including the newly identified se-
rotypes 6D, 6E and 11E, there are 46 different ser-
ogroups and 95 serotypes of S. pneumoniae that have
been described to date [4–6]. Conventional serotyping
by the Quellung reaction is complex, costly, and re-
quires highly skilled personnel. On the other hand,
latex agglutination is a simple and efficient alternative
method to Quellung reaction serotyping, but still needs
further work to improve its capacity to detect coloniz-
ing pneumococcal strains at low density [7]. In recent
years, a variety of DNA-based methods that rely on the
capsular polysaccharide synthesis locus for the detec-
tion of pneumococcal serotypes, have been described,
including approaches based on sequencing, restriction
fragment length polymorphisms, hybridization assays,
microarrays, and different PCR strategies [8–15]. For
many developing countries including China, it is crucial to
find a practical, simple and cost-effective strategy for rou-
tine serotype prediction and pneumococcal serogroup/
serotype surveillance.
In a previous study, Leung and collaborators used a
single PCR sequencing method targeting cpsB gene
(sequetyping) to identify S. pneumoniae serotypes [13].
The USA Centers for Disease Control and Prevention
(CDC) has published a sequential multiplex PCR (mPCR)
protocol, which, although is the most commonly used mo-
lecular assay for identification of S. pneumoniae serotypes,
is complicated by the need to perform eight sets of
multiplex PCRs. Here, we employed cpsB sequetyping
coupled with local based selective and modified sequen-
tial multiplex PCR, and serotypes 6A-6D specific PCRs,
to predict the serotypes of 193 S. pneumoniae isolates
from hospitalized children with pneumococcal infection
in our district hospital.
The aim of this study was, as a showcase, to investigate
the best combination of the aforementioned methods for
use as an initial serotype screening method especially for
developing countries. Furthermore, in order to provide
some local epidemiological data for current and future
planning purposes, we studied the serotype distribution,
antibiotic susceptibility and clinical presentation, amongst
the 193 S. pneumoniae isolates.
Methods
S. pneumoniae isolates
S. pneumoniae isolates (n =193) from children, were
provided by Shenzhen Bao’an Maternity & Child Health
Hospital, during the period January 2009 to December
2013. The identity of the isolates was confirmed using
standard microbiological tests, including colony morph-
ology, optochin susceptibility and bile solubility.
Among the 193 isolates, 169 (87.6 %) isolates were from
sputum, 17 (8.8 %) from blood, 3 (1.6 %) from pleural
fluid, 2 (1.0 %) from cerebrospinal fluid and 2 (1.0 %) from
other normally sterile body sites (Additional file 1: Table
S1). All the children with pneumonia imply satisfied the
World Health Organization standard definition for pneu-
monia, including classification as non-severe, severe and
very severe pneumonia [16]. The serotypes of all the iso-
lates were unknown at the time of receipt and testing.
When two isolates from the same subject had an identical
serotype, only one isolate was included in the study.
In children with pneumonia (severe or non-severe), spu-
tum was collected with a small suction catheter, which
was passed through the nose into the laryngopharynx.
The length of the catheter into the respiratory tract was
equal to the distance from the apex of the nose to the
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earlobe, and then to the thyroid cartilage. Upon eliciting a
cough reflex, respiratory tract secretions were aspirated.
In patients with very severe pneumonia who were under
mechanical ventilation, sputum was collected from an
endotracheal tube. The squamous epithelial cell numbers
of <10 per 10 x objective microscopic field was used as an
indicator of good quality sputum for culture [17], and only
samples that met this quality criteria were cultured.
The study was approved by the Medical Ethics
Committee of Shenzhen Bao’an Maternity & Child
Health Hospital affiliated with Jinan University (No.
S-2013002); and signed informed consents were ob-
tained from patient’s parents or guardians.
DNA extraction from bacterial isolates
Pneumococcal isolates were retrieved from storage by
subculture on blood agar plates (Columbia II agar base
supplemented with 5 % horse blood) and incubated
overnight at 37 °C in 5 % CO2. Genomic DNA was ex-
tracted from bacteria using the AxyGenamp DNA Mini
Extraction Kit (Axygen, USA) according to the manufac-
turer’s instructions, and the purified DNA was diluted in
a final volume of 100 μL Tris EDTA buffer and stored at
− 20 °C until use.
Building up a comprehensive 95 serotypes cpsB
sequetyping database based on GenBank sequences
(Additional file 2: Figure S1)
The previous cpsB sequetyping database designed by
Leung et al. [13] didn’t include all the 95 serotype cpsB se-
quences. Our aim was to extend this work by including all
the serotypes described to date in a new sequetyping data-
base. All the S. pneumoniae sequences in the GenBank
that contained the full-length of cpsB (as of Jan 1, 2015)
were downloaded, and after sequence alignment using
ClustalW and/or Blastn, each GenBank sequence was
given a unique cpsB sequetype name (see Additional file 3:
Table S2 and Additional file 2: Figure S1), ensuring that all
GenBank sequences with the same cpsB sequence, were
given the same sequetype name. The given cpsB sequetype
name was chosen to reflect the specific serotype (if only
one serotype had the sequence) or combination of sero-
types (when more than one serotype have a common
sequence) it represented. If multiple GenBank sequences
had an identical cpsB sequetype, only one GenBank
sequence was selected as reference to represent the seque-
type (Additional file 3: Table S2). All sequences for the 90
Statens Serum Institut serotype reference strains were
used as references for the relevant serotypes/sequetypes,
whilst for the other sequetype references, we used those
from Leung et al. [13] or other publications, and those
with longer cps gene cluster sequences, because they were
well-characterized compared with the other GenBank
sequences (Additional file 2: Figure S1). As shown in
Additional file 3: Table S2, if any of the reference se-
quences were longer than cpsB sequences (732-bp), the
position of full length of cpsB (732-bp) was clearly shown
on the GenBank sequences. Based on our database, all of
the S. pneumoniae full-length cpsB GenBank sequences
(as of Jan 1, 2015) with known serotypes and sequetypes
were included (see Additional file 3: Table S2 & Additional
file 2: Figure S1).
The cpsB sequetyping workflow for our local isolates
(Fig. 1)
The cpsB sequetyping was performed on all 193 S.
pneumoniae isolates as previously described [13] using
our newly designed comprehensive cpsB sequetyping
database, as shown in the workflow algorithm in Fig. 1.
In brief, as described by Leung et al. [13], a region
spanning the cpsB gene was amplified by single PCR,
the amplicon purified, and the nucleotide sequence de-
termined by double strand sequencing. The amplicon nu-
cleotide sequences were then used to Blastn GenBank
database, and if it was identical to any one or more of the
GenBank sequences, the serotype (s)/cpsB sequetype was
decided according to our cpsB sequetyping database (see
Additional file 3: Table S2). Any mismatch between the se-
quences and reference sequences in GenBank were manu-
ally checked to ascertain the mismatch. Furthermore,
USA CDC sequential multiplex PCRs were performed on
all 193 S. pneumoniae isolates, and serotypes 6A-6D
specific PCRs were performed on all serogroup 6 iso-
lates. The results were checked against cpsB sequetyp-
ing results, before submitting the new sequences to
GenBank (Additional file 4: Table S3).
Sequential multiplex PCR and local data based primer
sets selection
Sequential multiplex PCR, as per CDC scheme, was
employed to predict the isolate serotype(s) by targeting
serotype-specific cps regions [11]. The primer se-
quences, PCR reactions and product detection are as
published by the CDC and were updated in Feb 2014.
(http://www.cdc.gov/streplab/pcr.html). We further de-
signed combinations of primer sets in the first three reac-
tions to identify the six most predominant serotypes (19 F,
19A, 14, 23 F, 15, 6) in China based on previous studies
[18, 19], and three PCV7 vaccine serotypes (4, 9 V/9A,
18). In these modified reactions, reaction 1 contained
primers for serotypes 4, 6 and 18; reaction 2 contained
primers for serotypes 14, 9 V/9A, 15 F/15A and 19A; and
reaction 3 contained primers for serotypes 15B/15C, 19 F
and 23 F. If a sample was negative in the first three
reactions, eight sequential multiplex PCR reactions were
performed as previously described in CDC (USA) web-
page (http://www.cdc.gov/streplab/pcr.html).
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Serotypes 6A-6D specific PCRs
In a previous study, we developed serotype-specific PCR
to identify serotypes 6A, 6B, 6C and 6D [4]. Using the
same protocol and primers, sequential single PCRs were
performed with three primer sets to distinguish these
serotypes.
Antimicrobial susceptibility testing
In vitro susceptibility tests were performed using disk
diffusion and the following antibiotics were used;
erythromycin, clindamycin, levofloxacin, vancomycin,
tetracycline, sulfamethoxazole-trimethoprim and chlor-
amphenicol (Oxoid, UK). The minimum inhibitory
concentrations for penicillin and ceftriaxone were deter-
mined by E-test (AB Biodisk, Solna, Sweden). All tests
were performed following the United States Clinical
and Laboratory Standards Institute (CLSI) recommen-
dations, and CLSI M100-S25 version of the antibiotic
susceptibility breakpoints for S. pneumoniae was
adopted as criteria for determining drug resistance
[20]. S. pneumoniae ATCC 49619 was used as the
quality-control strain. Isolates not susceptible to three
or more classes of antimicrobials were considered
multidrug-resistant (MDR).
Statistical analysis
Data on serotype distribution of the isolates were ana-
lyzed using SPSS version 13.0 (SPSS Inc., Chicago, IL)
statistical software. Association between serotypes and
clinical presentation was tested using χ2 test or Fisher’s
exact test. A two-tailed cutoff of P < 0.05 was considered
statistically significant.
Fig. 1 The Streptococcus pneumoniae serotype prediction algorithm – a strategy based on cpsB sequetyping and selected mPCR. Step 1. The cpsB
sequetyping was performed on all 193 S. pneumoniae isolates. Sequencing results compared with cpsB sequetyping database. 21 different sequetypes
were identified; included serotype-specific sequetypes, sequetypes shared by multiple serotypes and novel cpsB sequetypes. Step 2. Modified and
selected USA CDC sequential multiplex PCR to double check, or resolve discrepant results, or identify those that shared the same cpsB sequetype. Step
3. Serotypes 6A-6D specific PCRs were performed for serogroup 6 isolates. Step 4. Submit all novel cpsB sequetypes to GenBank and update cpsB
sequetyping database
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Results
Clinical data
During the study period, 193 non-duplicate S. pneumoniae
isolates were collected from hospitalized children with
pneumococcal infections. The patients included 121 boys
and 72 girls; 126 (65.3 %) children were < 2 years old; 61
(31.6 %) were 2–5 years old; and 6 (3.1 %) were > 5 years
old. The distribution of cases by clinical presentation was
as follows: non-severe pneumonia (134, 69.4 %), severe
and very severe pneumonia (38, 19.7 %), primary
bacteremia (17, 8.8 %), meningitis (2, 1 %), urinary tract
infections (1, 0.5 %) and cellulitis (1, 0.5 %) (Additional
file 1: Table S1).
Development of reference cpsB sequence sequetyping
database
We developed a comprehensive S. pneumoniae serotype
cpsB sequence (732-bp) sequetyping reference database
for all the 95 described serotypes, including all 390 avail-
able GenBank sequences with full length of the cpsB se-
quence name (see Additional file 3: Table S2, Additional
file 2: Figure S1). When the same sequetype was shared
by two or more serotypes, the sequetype name included
all the different serotypes in ascending numerical order
(e.g., 24 F-24B-33 F-33A-35A-1).
The cpsB sequetyping results for studied clinical isolates
All the 193 isolates included in the study could be amp-
lified by cpsB PCR and yielded satisfactory sequencing
results (Table 1, Additional file 4: Table S3). Based on
cpsB sequence heterogeneity at one or more sites for all
isolates, 21 different sequetypes were identified: eight
serotype-specific sequetypes could predict isolates to
serotype level (3, 9 V, 6B, 10B, 14, 19A, 23 F, 23A); five
sequetypes shared by different serotypes but in the
same serogroups (6C-6D-1, 6B-6E-6X-1, 15B-15C-1,
19 F-19A-1, and 28 F-28A-1) could predict isolates to
the serogroup level; and three sequetypes shared by dif-
ferent serotypes - serotypes 13 and 20, 15A and 33B,
17A and 34, could not be differentiated from each
other. Of the 193 isolates tested, 66 (34.2 %) were
sequetyped to the serotype level and 107 (55.4 %) to the
serogroup level.
When the Blastn result was not a 100 % match with any
GenBank sequences, the sequences (if with good sequen-
cing quality for both directions) potentially represented
Table 1 Serotype distribution among 193 S. pneumoniae isolates as determined by cpsB sequetyping and selected sequential mPCR
Serotype/
Serogroup
No. of isolates with serotypes determined by Novel sequetypes
mPCR/6A-6D specific PCR cpsB sequetypinga
3 3 (n = 2) 1 bp-3-2 (n = 2) 3-sz-1 (3–5)
6A 6/6A (n = 12) 2 bp-6C-6D-1 (n = 12) 6A-sz-1 (6A-5)
6B 6/6B (n = 13) 6B-1 (n = 1)
6B-6E-6X-1 (n = 12)
6C 6/6C (n = 2) 6C-6D-1 (n = 2)
9 V/9A 9 V/9A (n = 3) 9 V-1 (n = 3)
10B unknown (n = 1)d 10B-1 (n = 1)
14 14 (n = 14) 14-1 (n = 14)
15 F/15A 15 F/15A (n = 2) 3 bp-15A-33B-1 (n = 2)b 15 F/15A-sz-1(15 F-15A-1)
15B/15C 15B/15C (n = 13) 15B-15C-1 (n = 13)
19 F 19 F (n = 67) 19 F-19A-1 (n = 67)
19A 19A (n = 23) 19A-2 (n = 23)
20 20 (n = 2) 13-20A-20B-1 (n = 2)b
23 F 23 F (n = 33) 23 F-1 (n = 20)
11 bp-11 F-1 (n = 9)c
6A-6B-6 F (n = 2)c
2 bp-6A-6B-6 F-1 (n = 1)c
13-20A-20B (n = 1)c
23 F-sz-1 (23 F-2)
23 F-6A-6B-6 F-sz-1
23 F-sz-2 (23 F-2)
23 F-13-20A-20B-1
23A 23A (n = 2) 23A-1 (n = 2)
28 F/28A unknown (n = 1)d 28 F-28A-1 (n = 1)
34 34 (n = 1) 17A-34-1 (n = 1) b
unknown unknown (n = 2)d unknown (n = 2)
a21 different sequetypes were identified
bFive isolates with ambiguous sequetype result, mPCR confirmed them
cThirteen 23 F isolates were of new sequetypes after mPCR was performed
dFour isolates were untypeable by mPCR. Two isolates were identified by cpsB sequetyping. Two isolates were also unknown by sequencing
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new cpsB sequetypes. For example, four new 23 F cpsB
sequetypes, confirmed by 23 F specific PCR were found
among thirteen 23 F isolates (Additional file 4: Table S3).
Among the 27 serogroup 6 isolates, the distribution of
sequetypes was as follows; 6B-1 (1/27, 3.7 %), 6C-6D-1
(14/27, 51.8 %), 6B-6E-6X-1 (12/27, 44.4 %). Two isolates
(ID 250, 268) produced cpsB amplicons but they were
non-typeable by both cpsB sequetyping and sequential
multiplex PCR (Additional file 4: Table S3).
Sequential multiplex PCR results
After cpsB sequetyping results were known, isolates that
presumptively belonged to relevant serotypes were further
tested by multiplex PCR to confirm the results, resolve
discrepant results, or identify those that shared the same
cpsB sequetype (Table 1, Additional file 4: Table S3, and
Fig. 1). Overall, 115 (59.5 %) of sequetyping results needed
confirmation by selected mPCR to give a definite serotype.
The level of agreement between cpsB sequetyping and
multiplex PCR results was 92.2 %. Five isolates, for
which sequencing gave ambiguous result as serotypes
15A-33B-1 (2 isolates), 13-20A-20B-1 (2 isolates), and
17A-34-1 (1 isolate), were confirmed by mPCR that
they were serotypes 15 F/15A, 20 and 34, respectively.
Thirteen serotype 23 F isolates belonging to four new
cpsB sequetypes, were assigned new sequetype names
after mPCR confirmed them as serotype 23 F. Four iso-
lates identified by cpsB sequetyping as 10B, 28 F/28A,
were non-typeable by mPCR because the serotype pri-
mer sets were not included in the USA CDC multiplex
reaction scheme (Table 1, Additional file 4: Table S3).
Two isolates (ID 250, 268 in Additional file 4: Table S3)
showed unknown sequetype in cpsB sequetyping, and
were also not amplified by any specific primer sets.
Serotypes 6A-6D specific PCRs results
The distribution of serotypes 6A-6D among the 27 ser-
ogroup 6 isolates were: 6A (12/27, 44.4 %), 6B (13/27,
48.1 %) and 6C (2/27, 7.4 %) and serotype 6D was not
detected.
Serotype distribution
Using the sequence-based method selectively supple-
mented with sequential multiplex PCR and serotypes
6A-6D specific PCRs strategy, sixteen serotypes were
identified from 193 S. pneumoniae isolates. They included
19 F (67, 34.7 %), 23 F (33, 17.1 %), 19A (23, 11.9 %), 14
(14, 7.3 %), 15B/15C (13, 6.7 %), 6B (13, 6.7 %), 6A (12,
6.2 %), 9 V/9A (3, 1.6 %); serotypes 6C, 3, 15 F/15A and
20 (2 each, 1.1 %); serotypes 10B, 28 F/28A and 34 (1 each,
0.5 %). The 10-valent PCV (PCV-10) vaccines cover
67.4 % of the serotypes identified, whilst the 13-valent
PCV (PCV-13) covers 86.5 %. A total of 126 isolates were
from patients less than 2 years of age, including 39 isolates
of serotypes 19 F (30.9 %), 23 of 23 F (18.3 %), 16 of 19A
(12.7 %), 10 of 15B/15C (7.9 %), 10 of 6A (7.9 %), 9 of 14
(7.1 %), 8 of 6B (6.3 %); 2 each of 20 and 15 F/15A (1.6 %);
and 1 each of 9 V/9A, 3, 34, 10B and 23A (0.8 %). PCV-10
covers 70.6 % of these strains whilst PCV-13 covers 92 %.
There was no significant difference between serotype dis-
tribution and clinical presentation (see Additional file 5:
Table S4).
Antimicrobial susceptibility
Susceptibility results for the S. pneumoniae isolates are
shown in Table 2. The resistance rates for erythromycin,
clindamycin, sulfamethoxazole-trimethoprim and tetra-
cycline, ranged from 87.6 to 97.4 %. According to the
revised CLSI breakpoints for parenteral penicillin, the
prevalence rates for penicillin resistance were 1.0 and
88.6 % in the non-meningitis and meningitis isolates, re-
spectively. The proportion of isolates resistant to ceftriax-
one was 5.2 % for non-meningitis, and 25.4 % for
meningitis isolates. All the isolates were susceptible to
vancomycin. The percentage of MDR isolates was
86.8 % (167/193), and the most common pattern was
resistance to erythromycin + clindamycin + sulfameth-
oxazole-trimethoprim (167/193, 86.8 %), followed by
resistance to erythromycin + clindamycin + sulfamethoxa-
zole-trimethoprim + tetracycline (150/193, 77.9 %), and
erythromycin + clindamycin + sulfamethoxazole-trimetho-
prim + tetracycline + chloramphenicol (22/193, 11.5 %).
Antibiotic resistance was clustered mainly in serotype
19 F, with resistant rates to parenteral penicillin, ceftriax-
one and erythromycin of 1.5, 14.9, and 97 % respectively.
The other half of the penicillin resistant isolates was
identified as serotype 23 F (3 %) (Additional file 6:
Table S5). For the penicillin, ceftriaxone parenteral re-
sistant non-meningitis isolates, the multidrug resistance
patterns were; erythromycin + clindamycin + sulfamethoxa-
zole-trimethoprim + tetracycline + chloramphenicol + peni-
cillin + ceftriaxone (n = 1); erythromycin + clindamycin +
sulfamethoxazole-trimethoprim + tetracycline + penicillin
+ ceftriaxone (n = 1); erythromycin + clindamycin + sulfa-
methoxazole-trimethoprim + tetracycline + ceftriaxone
(n =6); erythromycin + clindamycin + sulfamethoxazole-
trimethoprim + ceftriaxone (n =2).
Discussion
Most DNA-based methods allow the identification of a
limited number of S. pneumoniae serotypes or ser-
ogroups. Since not all of the 95 described capsular types
cause serious infections, it is important to develop a cap-
sular typing scheme targeting serotypes most frequently
associated with serious diseases [11]. In addition, after
introduction of the pneumococcal conjugate vaccines,
serotyping or serotype prediction assays are needed to
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monitor serotype switch from vaccine serotypes to non-
vaccine serotypes [21].
Because of the existence of 95 different S. pneumoniae
capsular types, it is difficult to develop a simple practical
molecular typing scheme based on genetic approaches.
In the present study, we developed a strategy to address
this challenge. To our knowledge, it is the most compre-
hensive cpsB sequetyping database to date. Having more
serotype sequetypes and sequetypes with multiple identi-
cal cpsB sequences in the sequetyping database, leads to
more accurate serotype prediction compared to Leung’s
study.
For most of our local isolates (except 2 non-
serotypeable), cpsB sequetyping would be a more straight-
forward way to predict serotypes. Although molecular
assays are generally considered unaffordable for most de-
veloping countries, PCR reagents are commonly available
in most laboratories in China, and are relatively inex-
pensive. Furthermore, commercial sequencing is also
affordable, convenient and cheap (~U$ 2.5/each reac-
tion) for the majority of clinical labs. In our laboratory,
cpsB sequencing is performed when a sufficient number
of samples have been submitted for a run, which makes
the cost very reasonable, and enables the lab to operate
more efficiently. However, we found that many GenBank
sequences share the same cpsB sequences (Additional
file 3: Table S2), between both related serotypes (antigenic
cross-reaction) and unrelated serotypes (no antigenic
cross-reaction), probably due to recombination events [22].
In this study, sequetyping characterized 34.2 % isolates to
serotype level and 55.4 % isolates to serogroup level. Multi-
plex PCR (mPCR) was needed to make a definite serotype
prediction or increase the serotype prediction accuracy.
But in most cases, cpsB sequetyping had already defined
the test isolates to a smaller serotype group range, which
made mPCR set selection much easier and saved from
having to perform eight sequential mPCR. We only needed
to resolve those cpsB sequetypes which were shared by
different serotypes (e.g., 13-20A-20B, 15A-33B, 17A-34) or
for isolates non-typeable by cpsB sequetyping (Fig. 1). In
fact, only 115 (59.5 %) of sequetyping results needed to be
confirmed by selected sets of mPCR in this study.
Furthermore, using the mPCR, most serotypes were
identified in the first three sets of mPCR reactions, and
only seven (3.6 %) isolates required further testing of up
to eight sequential sets of multiplex reactions. After we
update our new cpsB sequetyping database in the future,
the number of isolates requiring mPCR confirmation
would be much less than 59.5 % isolates, with most of
them identified in the first three mPCR reactions. We
also identified some new sequetypes within serotypes
23 F, 6A, 15 F/15A, 3 and rare serotype 20, which will
improve the serotype prediction accuracy besides redu-
cing the necessity of performing eight sequential multi-
plex reactions.
Although molecular methods are becoming increasingly
utilized for pneumococcal typing, phenotypic methods in-
cluding Quellung reaction and latex agglutination, remain
the most reliable way to discover possible false-positive
PCR results, which is fairly rare, but can occur (Fig. 1)
[23]. However, some isolates are genotypeable by micro-
array or sequencing, but non-typeable by the Quellung re-
action and latex agglutination [10, 24], suggesting caution
must be exercised when interpreting controversial results
Table 2 Prevalence of antibiotic susceptibility to nine antimicrobials for 193 S. pneumoniae isolates from children
Antimicrobial No. (%) of isolates MIC (ug/mL)
Susceptible Intermediate Resistant MIC50 MIC90 Range
Penicillin 0.016–8.0
Non-meningitis isolates
Parenteral 176 (91.2) 15 (7.8) 2 (1.0) 1 2
Oral 22 (11.4) 95 (49.2) 76 (39.4) 1 2
Meningitis isolates 22 (11.4) 0 (0) 171 (88.6) 1 2
Ceftriaxone 0.016–6.0
Non-meningitis isolates 144 (74.6) 39 (20.2) 10 (5.2) 0.75 2
Meningitis isolates 83 (43.0) 61 (31.6) 49 (25.4) 0.75 2
Erythromycin 2 (1.0) 3 (1.6) 188 (97.4)
Vancomycin 193 (100) 0(0) 0(0)
Levofloxacin 191 (99) 2 (1.0) 0 (0)
Tetracycline 9 (4.7) 12 (6.2) 172 (89.1)
Chloramphenicol 168 (87.0) 0 (0) 25 (13)
Sulfamethoxazole-trimethoprim 14 (7.3) 10 (5.2) 169 (87.6)
Clindamycin 5 (2.6) 1 (0.5) 187 (96.9)
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(Fig. 1). In reality, genotyping, no matter how accurate it
is, is only a method for prediction of serotypes/serogroups,
not a replacement method for conventional serotyping,
because “serotype” is traditionally a phenotypic rather than
a genotype based definition.
The distribution of S. pneumoniae serotypes differ by
geographic region. Several studies conducted over the
years in China demonstrated great diversity in the dis-
tribution of S. pneumoniae serotypes by region [25, 26].
Bao’an district, the biggest administrative region in
Shenzhen City, has a population of 6 million, of which
90 % are floating (temporary) residents as this city
shares a border with Hong Kong. In this region, the
immunization level for PCV7 vaccine has been less
than 1 % for the past 5 years. Our study identified 16
serotypes, seven (19 F, 23 F, 19A, 14, 15B/15C, 6B and
6A) of which accounted for 90.7 % of the isolates,
which is in general agreement to another study in
Shenzhen [3]. Furthermore, our study confirmed previ-
ous findings showing that serotype 19A is one of the
most common serotypes in Shenzhen [3] and China
[27], which is not related to the introduction of PCV-7
vaccine, but to widespread antimicrobial use, similar to
the situation in Korea [28]. A further 15 (7.8 %) of the
193 isolates belonged to serogroup 15 (2 serotype 15 F/
15A isolates; 13 serotype 15B/15C isolates), which is
quite similar to the pre-PVC7 period proportion in
Hong Kong for serogroup 15 (5.7 %) [29].
It has been reported that serotypes 1, 2, 7, 9, 14, and
16 are among the most invasive serotypes, whilst sero-
types 3, 6, 15, 19, and 23 are considered least invasive
serotypes [30, 31]. However, Picazo et al. reported that
serotype 19A was linked to non-respiratory IPDs in chil-
dren of <24 months [32], whilst Hausdorff et al. found
that serotypes 1 and 14 were more often isolated from
blood, and serogroups 3, 19, and 23, more often isolated
from middle ear fluid [33]. In the present study, no signifi-
cant differences were noted between serotype and clinical
presentation, which could be due to limited number of
isolates and/or disease categories studied.
Prevention of pneumococcal disease includes vaccin-
ation with pneumococcal polysaccharide conjugate vac-
cines especially in children. Based on the distribution of
serotypes in all patients in our study population (age from
27 days to 6 years and 5 months), the PCV-10 vaccine
would cover 67.4 % of the serotypes, whilst the PCV-13
vaccine would cover 86.5 % of the serotypes found in the
area. The major target population for vaccination and pre-
vention is children under 2 years of age. PCV-13 still
showed higher coverage (92 %) in <2 year old patients in
our study population compare to PCV-10 (70.6 %). Specif-
ically, the significantly increased coverage by PCV13 in
our study population is due to high prevalence of sero-
types 19A (23, 11.9 %) and 6A (12, 6.2 %), which together
with serotype 3, are contained in the PCV-13 vaccine but
not in the PCV-10 [3]. These findings suggest that PCV-
13 should be the major target for future development and
applications in our community, since PCV-7 is no longer
available, and PCV-10 has less coverage.
The low prevalence rate of parenteral penicillin resist-
ance (1.0 %) among the non-meningitis isolates in our
study is noted, and suggests that hospitalized children
with non-meningitis pneumococcal infections can be
treated with parenteral penicillin. It has been reported
that seven (6A, 6B, 9 V, 14, 19A, 19 F, 23 F) out of 95
serotypes are associated with antibiotic resistance [34].
Interestingly, these seven serotypes accounted for 85.5 %
of our 193 isolates, which could explain the high preva-
lence rate of multidrug resistance (86.8 %) in the present
study (Additional file 6: Table S5).
This study has several limitations. First, the number of
isolates from blood and cerebrospinal fluid was small,
which limited statistical power. Furthermore, 87.6 %
isolates were from sputum, some of which may be col-
onizing organisms since certain S. pneumoniae serotypes
have a propensity for colonization without necessarily
causing disease. However, it is believed that invasive
disease originates from colonization and that serotype
distribution among colonizing strains, is an indicator of
the diversity of pneumococcal strains circulating in the
community [35]. Furthermore, our sputum specimen
sampling strategy, including using the quality criteria,
would have minimized the level of contamination from
colonizing strains. Secondly, all data presented here is
from one of the biggest district hospitals, so we can’t
overplay the data to represent more rural regions though
it would be representative of our Bao’an District hospi-
talized children.
Conclusions
This study provides a cost-effective alternative S. pneu-
moniae serotype prediction strategy to conventional
serotyping. We showcased the utility of this new sero-
typing strategy by identifying serotypes of 193 S. pneu-
moniae isolates from children. This strategy enables
most routine laboratories equipped with PCR to predict
the majority of pneumococcal serotypes without the need
for an expensive set of serological reagents in China. This
study confirms that serotype 19A is common in China,
and that PCV13 vaccine would be important for future
vaccination in areas such as Shenzhen. Considering the
low resistance rate in non-meningitis isolates to paren-
teral penicillin, clinicians should be encouraged to in-
crease the use of penicillin to treat penicillin-susceptible
non-meningitis pneumococcal infections, instead of using
broader-spectrum antimicrobials. Continued surveillance
of the serotype distribution and antimicrobial susceptibil-
ity of S. pneumoniae isolates in China is warranted.
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